Zacks Investment Research upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a research report released on Monday morning. Zacks Investment Research currently has $3.75 price target on the biotechnology company’s stock.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
CGEN has been the topic of a number of other research reports. ValuEngine lowered shares of Compugen from a hold rating to a sell rating in a research note on Wednesday, March 7th. CIBC assumed coverage on shares of Compugen in a research report on Thursday, March 29th. They set an outperform rating for the company. Finally, Oppenheimer assumed coverage on shares of Compugen in a research report on Thursday, March 29th. They set an outperform rating and a $9.00 price target for the company. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $8.92.
CGEN opened at $3.35 on Monday. Compugen has a 52-week low of $3.40 and a 52-week high of $3.50.
Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter. equities research analysts forecast that Compugen will post -0.44 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in CGEN. ARK Investment Management LLC grew its position in shares of Compugen by 95.9% during the fourth quarter. ARK Investment Management LLC now owns 2,253,416 shares of the biotechnology company’s stock worth $5,634,000 after buying an additional 1,103,384 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Compugen during the fourth quarter worth approximately $2,381,000. UBS Group AG grew its position in shares of Compugen by 1,813.2% during the first quarter. UBS Group AG now owns 316,066 shares of the biotechnology company’s stock worth $1,406,000 after buying an additional 299,546 shares in the last quarter. Taylor Frigon Capital Management LLC acquired a new stake in shares of Compugen during the fourth quarter worth approximately $707,000. Finally, Anson Funds Management LP acquired a new stake in shares of Compugen during the fourth quarter worth approximately $281,000. 19.42% of the stock is owned by institutional investors and hedge funds.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations.
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.